Scientists Uncover the Hidden Mechanism Behind FDA-Approved Alzheimer’s Drug

Scientists show that lecanemab clears amyloid plaques by engaging microglia through its Fc fragment, defining the cellular program behind its therapeutic effect Lecanemab, marketed as Leqembi, is a monoclonal antibody treatment for Alzheimer’s disease that reduces the buildup of toxic amyloid plaques in the brain and slows cognitive decline. Scientists from VIB and KU Leuven […] Read More